Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348283 · ClinicalTrials.gov registry record · Phase 3
Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
NCT00348283 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 135 participants.
The verdict
NCT00348283, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
Study Summary
The goal of this study was to test whether adalimumab can induce mucosal healing in subjects with moderate to severe ileocolonic Crohn's Disease.
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00348283
The ClinicalTrials.gov registry entry for NCT00348283 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00348283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00348283 about?
NCT00348283 is a clinical study titled "Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon". The goal of this study was to test whether adalimumab can induce mucosal healing in subjects with moderate to severe ileocolonic Crohn's Disease.
What is the current status of trial NCT00348283?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2006-08.
What interventions are being tested in trial NCT00348283?
The interventions under investigation include: placebo (BIOLOGICAL), adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00348283?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.